The new government in Novo Nordisk A/S’s home country of Denmark wants to test whether weight-loss drugs can help get more people into work, adding a new economic dimension to the debate over obesity treatments.
The new government in Novo Nordisk A/S’s home country of Denmark wants to test whether weight-loss drugs can help get more people into work, adding a new economic dimension to the debate over obesity treatments.
Denmark was among the first countries where Novo launched Wegovy, in late 2022. Photographer: Hilary Swift/Bloomberg
Login
